Authors
Latest:
Need for More Creative, Head-to-Head Migraine Trials: Jessica Ailani, MDThe director of the MedStar Georgetown Headache Center detailed how creative and comparative clinical trials can drive treatment personalization and strengthen clinical confidence. [WATCH: 4 minutes]
Latest:
FibroGen's Duchenne Muscular Dystrophy Antibody Pamrevlumab Falls Short in Phase 3The study did not meet its primary end point of change from baseline in Performance of the Upper Limb 2.0 score at 1 year.
Latest:
FDA Rejects Duchenne Muscular Dystrophy Drug Golodirsen, Citing Safety ConcernsThe regulatory agency cited 2 concerns in the complete response letter: the risk of infections related to intravenous infusion ports and renal toxicity.
Latest:
Unusual New Onset Seizures in a Healthy, Young Adult MaleA 23-year-old male college student presents with first generalized tonic-clonic seizure followed by episodes of violent psychosis.
Latest:
FDA Approves Vutrisiran for ATTR-CM, Expanding Indication in AmyloidosisMarketed as Amvuttra, the Alnylam Pharmaceuticals RNA-interference treatment is now approved for an additional patient population of 150,000 in the US, and more than 300,000 worldwide.
Latest:
Using the Ketogenic Diet to Treat Intractable Epilepsy in Case of Glycine EncephalopathyA boy diagnosed with glycine encephalopathy in the newborn period was initiated on the ketogenic diet at 11 years-old for the treatment of medication refractory epilepsy.
Latest:
Understanding Cerebral Venous Thrombosis: Rare But Sometimes FatalThe prognosis of cerebral venous thrombosis (CVT) is favorable compared with other types of stroke: almost 80% of patients with CVT recover without functional disability. Nevertheless, 5% to 10% of patients die in the acute phase.
Latest:
Understanding Cerebral Venous Thrombosis: Rare But Sometimes FatalThe prognosis of cerebral venous thrombosis (CVT) is favorable compared with other types of stroke: almost 80% of patients with CVT recover without functional disability. Nevertheless, 5% to 10% of patients die in the acute phase.
Latest:
Understanding Cerebral Venous Thrombosis: Rare But Sometimes FatalThe prognosis of cerebral venous thrombosis (CVT) is favorable compared with other types of stroke: almost 80% of patients with CVT recover without functional disability. Nevertheless, 5% to 10% of patients die in the acute phase.
Latest:
Case Report: New Onset Paroxysmal Episodes in an InfantA newborn presents with new onset episodes of lateral gaze deviation with extremity stiffening.
Latest:
Closing the Treatment Gap in Progressive MSNew biomarkers of disease activity may help better vet investigational therapies aimed at slowing the insidious neurodegeneration seen in primary progressive multiple sclerosis.
Latest:
Merz’ IncobotulinumtoxinA Begins Phase 3 MINT Trials for Migraine PreventionMerz initiates phase 3 trials for Xeomin, targeting migraine prevention in adults, aiming to fill gaps in current treatment options.
Latest:
Cyclic Vomiting, Incontinence in a Young BoyAn 8 year old boy with genetically confirmed neurofibromatosis type 1 presents with first generalized seizure.
